Calgary's Tom Baker Cancer Centre manages myeloma and lymphoma patients requiring proteasome inhibitor therapy. Bortenat 3.5mg provides identical treatment to brand Velcade at significantly reduced institutional cost.
Calgary oncology pharmacies can source Bortenat with full WHO-GMP documentation for hospital formulary approval, offering substantial savings on this essential cancer medicine.
|
FAQ: Is there a difference in effectiveness between
subcutaneous and IV Bortenat? Clinical studies have
demonstrated equivalent efficacy between subcutaneous and intravenous
administration of Bortezomib for treating multiple myeloma. The key
difference is safety — subcutaneous administration significantly reduces the
risk of peripheral neuropathy, which is why most cancer centres, including
those in Calgary, have shifted to this route as standard practice. |
